# reload+after+2024-01-23 15:44:59.785032
address1§60-66 Hanover Street
city§Fitzroy
state§VIC
zip§3065
country§Australia
phone§61 3 8412 7000
fax§61 3 8412 7040
website§https://genetype.com
industry§Diagnostics & Research
sector§Healthcare
longBusinessSummary§Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the United States, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates in two segments, EasyDNA and GeneType/Corporate. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, and type 2 diabetes. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.
fullTimeEmployees§60
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Simon  Morriss', 'title': 'Chief Executive Officer', 'fiscalYear': 2023, 'totalPay': 266459, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Tony  Di Pietro AGIA, B.Com, C.A., CPA, M.A.I.C.D.', 'title': 'CFO & Company Secretary', 'fiscalYear': 2023, 'totalPay': 197701, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Carl S. Stubbings BSc', 'title': 'Chief Commercial Officer', 'fiscalYear': 2023, 'totalPay': 176504, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kevin  Camilleri', 'title': 'Chief Executive Officer of EasyDNA', 'fiscalYear': 2023, 'totalPay': 170341, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Paul Keith Mathieson Viney B. Bus, FCI, FCPA, FGIA', 'title': 'Consultant', 'fiscalYear': 2023, 'totalPay': 121301, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.435
priceToSalesTrailing12Months§1.0844452
currency§USD
dateShortInterest§1702598400
exchange§NCM
quoteType§EQUITY
shortName§Genetic Technologies Ltd
longName§Genetic Technologies Limited
firstTradeDateEpochUtc§1126013400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§1fb68761-2b24-3dda-ac8c-b9635b9462c6
gmtOffSetMilliseconds§-18000000
recommendationKey§none
quickRatio§2.956
grossMargins§0.58105
ebitdaMargins§-0.96986
trailingPegRatio§None
